Somewhat Positive Press Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Stock Price

News articles about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6637361342847 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Esperion Therapeutics (NASDAQ:ESPR) traded up $0.23 on Wednesday, reaching $55.81. 346,518 shares of the company traded hands, compared to its average volume of 1,042,030. Esperion Therapeutics has a 1-year low of $10.30 and a 1-year high of $57.67.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the company earned ($0.77) EPS. analysts expect that Esperion Therapeutics will post -7.21 EPS for the current fiscal year.

Several research firms recently commented on ESPR. Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price target (up from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Northland Securities restated a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Finally, Bank of America Corporation restated a “neutral” rating and issued a $60.00 price target on shares of Esperion Therapeutics in a research note on Friday, August 11th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Esperion Therapeutics has an average rating of “Buy” and an average price target of $58.92.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Stock Price” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/11/22/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-esperion-therapeutics-espr-stock-price.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit